Discover how MDRS provides a regulatory-accepted alternative to clinical endpoint studies for nasal suspension bioequivalence. Learn to de-risk your ANDA pathway today.

Discover how automated pMDI actuation improves consistency and reduces analyst variability in in vitro bioequivalence testing, supporting realistic APSD analysis and FDA expectations.